Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr496 Inhibitors

Olr496 inhibitors represent a specific class of compounds that are designed to target and modulate the activity of the Olr496 protein, which is a member of the olfactory receptor family. Olfactory receptors, typically involved in the detection of odorant molecules, belong to a large family of G-protein-coupled receptors (GPCRs), which are known for their significant role in signal transduction processes across cell membranes. The inhibition of Olr496 involves binding to the receptor in a way that either prevents its activation by natural ligands or interrupts the downstream signaling cascade that would normally result from such activation. This can lead to alterations in the signaling pathways associated with the receptor, which may influence various physiological processes depending on the distribution and specific functions of Olr496 in different tissues or systems.

Structurally, Olr496 inhibitors may vary widely, but they often share key features that allow them to effectively interact with the Olr496 binding site. These features could include specific aromatic or heterocyclic rings that facilitate binding through hydrophobic interactions or hydrogen bonding with the receptor's active site. Additionally, many Olr496 inhibitors are designed to possess sufficient lipophilicity, ensuring their ability to cross cellular membranes and reach the receptor embedded within the lipid bilayer. The design and synthesis of these inhibitors typically involve a combination of computational modeling, structure-activity relationship (SAR) studies, and biochemical assays to optimize their affinity and selectivity for Olr496. Such inhibitors can serve as powerful tools for probing the biological functions of Olr496 in various non-clinical research settings, contributing to a deeper understanding of olfactory receptor mechanisms and GPCR signaling as a whole.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

CH5424802

1256580-46-7sc-364461
sc-364461A
5 mg
50 mg
$191.00
$902.00
(0)

Selectively inhibits ALK tyrosine kinase, potentially affecting proteins in ALK-driven signaling pathways.

ABT-199

1257044-40-8sc-472284
sc-472284A
sc-472284B
sc-472284C
sc-472284D
1 mg
5 mg
10 mg
100 mg
3 g
$118.00
$337.00
$520.00
$832.00
$1632.00
10
(0)

BCL-2 inhibitor, potentially influencing proteins involved in apoptosis and cell survival.

Ibrutinib

936563-96-1sc-483194
10 mg
$156.00
5
(0)

Inhibits Bruton's tyrosine kinase, potentially affecting proteins in B-cell receptor signaling.

Vismodegib

879085-55-9sc-396759
sc-396759A
10 mg
25 mg
$82.00
$158.00
1
(0)

Inhibits Hedgehog signaling pathway, potentially affecting proteins involved in cell growth and differentiation.

Pazopanib

444731-52-6sc-396318
sc-396318A
25 mg
50 mg
$130.00
$182.00
2
(1)

Inhibits VEGF receptors, potentially affecting proteins involved in angiogenesis and tumor growth.

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$87.00
$135.00
$293.00
$505.00
$3827.00
42
(0)

Inhibits EGFR tyrosine kinase, potentially affecting proteins in the EGFR signaling pathway.

Dabrafenib

1195765-45-7sc-364477
sc-364477A
sc-364477B
sc-364477C
sc-364477D
5 mg
25 mg
50 mg
100 mg
10 g
$141.00
$260.00
$278.00
$411.00
$12485.00
6
(1)

BRAF inhibitor, potentially affecting proteins involved in the MAPK/ERK pathway.

Regorafenib

755037-03-7sc-477163
sc-477163A
25 mg
50 mg
$320.00
$430.00
3
(0)

Multi-kinase inhibitor, potentially affecting proteins in angiogenesis, oncogenesis, and the tumor microenvironment.

Osimertinib

1421373-65-0sc-507355
5 mg
$86.00
(0)

Inhibits EGFR with T790M mutation, potentially affecting proteins in mutated EGFR pathways.

XL-184 free base

849217-68-1sc-364657
sc-364657A
5 mg
10 mg
$94.00
$208.00
1
(1)

Inhibits MET, VEGFR, and RET, potentially affecting proteins in multiple signaling pathways.